In discussion with Dr. Rachna Shroff, covering the ESMO 2023 GI Cancer Highlights from Community Oncology perspective. We covered 3 important practice informing studies with Dr. Shroff:
- Codebreak300 – Sotorasib plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer
- CABINET – Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus
- GASTFOX – Evaluate FOLFOX With or Without Docetaxel (TFOX) as First Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma
#ESMO #PrecisionMedicine #GICancer #2023 #cancer #oncology #oncbrothers
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Contact us at info@oncbrothers.com
ESMO 2023 GI Cancer Highlights – Codebreak300, CABINET, GASTFOX
Теги
canceroncologychemotherapytherapyguidelinesnccnsummaryOncBrothersbrothersHighlightsOncrohitgosainrahulvideoabtractsocietyamericanoncdrdoctordr.healthcaremedicinemedicaloncbrotherspracticechangingmalignancymalignantchemotreatmentprognosisclinicstagetdxdfdacommunityoncologistchiefliuprofessorassociatect2023ascoesmocodebreaksotorasibpanitumumabneuroendocrinetumornetshroffdirectorarizonacenteruniversitylewismarksaabgicabinetfolfox
